Ann Dermatol.  2017 Dec;29(6):826-827. 10.5021/ad.2017.29.6.826.

A Type II Segmental Vitiligo Developed under Infliximab Treatment for Ulcerative Colitis

• Ryu TH
• Lee DW
• Choi JE
• Ahn HH
• Kye YC
• Seo SH

• KMID: 2395206
• DOI: http://doi.org/10.5021/ad.2017.29.6.826

Abstract

No abstract available.

MeSH Terms

Colitis, Ulcerative*
Infliximab*
Ulcer*
Vitiligo*
Infliximab

Reference

1. Webb KC, Tung R, Winterfield LS, Gottlieb AB, Eby JM, Henning SW, et al. Tumour necrosis factor-α inhibition can stabilize disease in progressive vitiligo. Br J Dermatol. 2015; 173:641–650.

2. Toussirot É, Aubin F. Paradoxical reactions under TNF-α blocking agents and other biological agents given for chronic immune-mediated diseases: an analytical and comprehensive overview. RMD Open. 2016; 2:e000239.

3. Ramírez-Hernández M, Marras C, Martínez-Escribano JA. Infliximab-induced vitiligo. Dermatology. 2005; 210:79–80.

4. Snook JA, de Silva HJ, Jewell DP. The association of autoimmune disorders with inflammatory bowel disease. Q J Med. 1989; 72:835–840.

5. Song MS, Hann SK, Ahn PS, Im S, Park YK. Clinical study of vitiligo. Ann Dermatol. 1994; 6:22–30.